Application

Anti-Vinculin, clone 3M13 ZooMAb, Cat. No. ZRB1089, is a recombinant Rabbit monoclonal antibody that targets Vinculin and has been tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Quality Control TestingWestern Blotting Analysis: A 1:10,000 dilution of this antibody detected Vinculin in NIH3T3 cell lysate.Tested applicationsWestern Blotting Analysis: A 1:10,000 dilution from a representative lot detected Vinculin in lysates from HeLa, Cos-7, L6 cells and mouse heart tissue.Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected Vinculin in human prostate tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Vinculin in HeLa, A431, HepG2, and NIH 3T3 cells.Affinity Binding Assay: A representative lot of this antibody bound Vinculin peptides with a KD of 3.3 x 10-7 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal half of human Vinculin.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 3M13 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Vinculin. It targets an epitope within 25 amino acids from the C-terminal half.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Vinculin (UniProt: P18206; also known as Metavinculin, MV) is encoded by the VCL gene (Gene ID: 7414) in human. Vinculin is a muscle-specific, peripheral membrane protein that serves as an actin filament binding protein involved in cell-matrix adhesion and cell-cell adhesion. It regulates cell-surface E-cadherin expression and potentiates mechano-sensing by the E-cadherin complex. Its recruitment to cell-cell junctions is reported to occur in a myosin II-dependent manner and its interaction with catenin-b1 is shown to be essential for its localization to the cell-cell junctions. Vinculin exists in at least two conformations. When in the closed, ′inactive′ conformation, extensive interactions between its head and tail domains prevent detectable binding to most of its ligands. It takes on an ′active′ conformation after cooperative and simultaneous binding of two different ligands. This activation involves displacement of the head-tail interactions. The active form binds a number of proteins that have both signaling and structural roles that are important for cell adhesion. The N-terminal globular head (aa 1-835; Vh) contains subdomains D1-D4. The C-terminal tail (aa 879-1134; Vt) region binds F-actin and cross-links actin filaments into bundles. An intramolecular interaction between Vh and Vt regions masks the F-actin-binding domain that is located in Vt region. Mutations in VCL gene are reported to cause familial hypertrophic cardiomyopathy that is characterized by asymmetric ventricular hypertrophy leading to dyspnea, syncope, collapse, palpitations, and chest pain. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.